drugset / Trial / NCT02876835

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

NCT02876835

Phase 3 Completed 3872 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this multi-center event-driven study in non-dialysis (ND) participants with anemia associated with chronic kidney disease (CKD) is to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.

Timeline

Start
2016-09-27
Primary completion
2021-04-19
Completion
2021-04-19

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Daprodustat Small molecule Oral
Comparator Darbepoetin alfa Protein / enzyme biologic Subcutaneous

Indications